Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00116831 · ClinicalTrials.gov registry record · Phase 3
Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 672
- Enrollment target
NCT00116831 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 672 participants.
The verdict
NCT00116831, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 672 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and effectiveness of rosiglitazone against a sulfonylurea in reducing or slowing the development of atherosclerosis in the blood vessels of the heart.
Interventions
- DRUG Glipizide
- DRUG rosiglitazone maleate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 672 participants |
| Start Date | 2005-01 |
| Est. Completion | 2008-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00116831
The ClinicalTrials.gov registry entry for NCT00116831 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 672 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Glipizide is the first listed.
NCT00116831 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00116831 about?
NCT00116831 is a clinical study titled "Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes". The purpose of this study is to test the safety and effectiveness of rosiglitazone against a sulfonylurea in reducing or slowing the development of atherosclerosis in the blood vessels of the heart.
What is the current status of trial NCT00116831?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 672 participants. The study started on 2005-01. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00116831?
The interventions under investigation include: Glipizide (DRUG), rosiglitazone maleate (DRUG).
Who is sponsoring clinical trial NCT00116831?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.